MDClone Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Beer-Sheva, ISR Israel
Total Funding:N/A
Industry:Tech Services
Founded:2015
Lead Investor(s):N/A

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • MDClone's estimated annual revenue is currently $11.3M per year.(?)
  • MDClone's estimated revenue per employee is $145,000

Employee Data

  • MDClone has 78 Employees.(?)
  • MDClone grew their employee count by 24% last year.
  • MDClone currently has 1 job openings.

MDClone introduces a groundbreaking environment for data-driven healthcare exploration, discovery and delivery. The MDClone Healthcare Data Platform liberates data - leveraging the temporal nature of healthcare data, unprecedented privacy protection, and modern big data technologies to enable never-before-possible operational insights, unlimited hypothesis testing, and zero-risk data sharing - all to transform healthcare. The Platform is based on MDClone's proprietary healthcare oriented data engine and Synthetic Data Engine, powering real-time retrieval of data based on longitudinal events with 100% unidentified synthetic data. Any question, cohort or population and any data element from any source can be analyzed, all in familiar terminologies without programming skills or mediators, and all with zero-risk to patient privacy. In less than two years, we've has partnered with over 80% of the Israeli healthcare market (including the top hospitals and largest HMOs), streamlining healthcare operations, empowering researchers and creating new opportunities for technology development. In 2018, we began our first major project in the U.S. with Washington University School of Medicine in St. Louis. MDClone launched in 2016 in Beer-Sheva, Israel, led by the founding team of dbMotion, Israel's most successful healthcare IT company (acquired by U.S.-based Allscripts in 2013 for $235 million). We're a growing 35-person team with offices in the U.S. (Chicago and St. Louis) and Europe, backed by investments from Orbimed and Lightspeed Ventures.

keywords:N/A